News
Featured Image
 shutterstock.com

(LifeSiteNews) – Project Veritas’ latest undercover video reveals a Pfizer scientist recounting one instance of a superior expressing disinterest in the apparent failure of the company’s COVID-19 vaccine to impart immunity to a test subject.

The video, released Friday, shows a snippet of a conversation with Pfizer scientist Nick Karl, who tells an undercover Veritas journalist of his “first experiment” with the vaccine on a subject who “got the vax twice and had no antibody response.” At first, he thought the sample had simply been mislabeled, but his unnamed superior’s reaction was allegedly indifference.

“Like I was, like, questioning it, and my boss was like, ‘who cares, like it just didn’t work,’” Karl says. “I’m like, ‘what?’”

“He didn’t want me to investigate it further,” Karl continued. “He was like, ‘I really don’t care about this one sample that didn’t work.’ I guess there’s a small percentage where it just doesn’t work.”

The video is the latest in a series of exposes Project Veritas has published on the COVID vaccines generally and Pfizer specifically. It comes as a growing body of data indicates that mass vaccination is failing to curb the spread of the virus. The federal government considers more than 65% of eligible Americans “fully vaccinated” (a designation that has lost meaning in light of growing evidence that vaccine effectiveness wears off in a matter of months), yet ABC News reported last week that more Americans died of COVID-19 this year (353,000) than in all of 2020 (352,000), according to data from Johns Hopkins University.

Last month, The Blaze senior editor Daniel Horowitz noted that the Pfizer vaccine enjoyed the most favorable treatment from the federal government of all the COVID vaccines, including quasi-FDA approval and permission to administer third shots, despite data finding it to be less effective than the Moderna shot.

Across the nation, significant concerns remain about the safety of all three COVID-19 vaccines (from Pfizer, Moderna, and Johnson & Johnson) used in the United States, which stem from the fact that they were developed and released far faster than any previous vaccine.

Vaccine defenders note that the one-year development period was not starting from scratch, but rather relied on years of prior research into mRNA technology; and that one of the innovations of the Trump administration’s “Operation Warp Speed” was conducting various aspects of the development process concurrently rather than sequentially, eliminating delays unrelated to safety. However, those factors do not fully account for the condensing of clinical trial phases — each of which can take anywhere from 1-3 years on their own — to just three months apiece. 

While cases of severe harm reported to the federal Vaccine Adverse Events Reporting System (VAERS) after taking COVID shots represent less than one percent of total doses administered in the United States, a 2010 report submitted to the US Department of Health & Human Services’ (HHS) Agency for Healthcare Research and Quality (AHRQ) warned that VAERS caught “fewer than 1% of vaccine adverse events.” May reporting from NBC News quotes several mainstream experts acknowledging “gaps” in federal vaccine monitoring.

LifeSiteNews has produced an extensive COVID-19 vaccines resources page. View it here

Comments

Commenting Guidelines

LifeSiteNews welcomes thoughtful, respectful comments that add useful information or insights. Demeaning, hostile or propagandistic comments, and streams not related to the storyline, will be removed.

LSN commenting is not for frequent personal blogging, on-going debates or theological or other disputes between commenters.

Multiple comments from one person under a story are discouraged (suggested maximum of three). Capitalized sentences or comments will be removed (Internet shouting).

LifeSiteNews gives priority to pro-life, pro-family commenters and reserves the right to edit or remove comments.

Comments under LifeSiteNews stories do not necessarily represent the views of LifeSiteNews.